ECL vs EDIT · P/E 35, rev $4.01B vs rev $32.3M
Ecolab Inc (ECL) versus Editas Medicine Inc (EDIT) — a side-by-side from cached financials, not a winner call.
Ecolab Inc (ECL) is a specialty chemicals company listed on US.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Latest reported ECL revenue for 2024-12-31 was $4.01B. Net income was $2.13B. Revenue was up 0.2% from 2024-09-30 to 2024-12-31. ECL currently screens at market cap $72.05B and trailing P/E 34.6.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
ECL currently screens at market cap $72.05B and trailing P/E 34.6. EDIT currently screens at market cap $375.2M.
Not investment advice. Open the ECL and EDIT stock pages for the full models.
Not investment advice.